All News

Amy Pearlman, MD, and Rachel Rubin, MD, discuss groundbreaking guidelines in sexual health, emphasizing education, and patient empowerment.

The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.

"Suctioning technology for mini-PCNL is an improvement on relying on passive outflow," says Mantu Gupta, MD.

SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.

In this episode, Gregory E. Tasian, MD, MSc, MSCE, Jonathan S. Ellison, MD, and patient partner Annabelle Pleskoff reflect on the origins, design, and key findings of the PKIDS trial.

"My pragmatic takeaway is that for patients who experience spasm or leak despite anticholinergics, this is a great thing to consider," says Mark D. Tyson II, MD, MPH.

The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

MacDonald underscores the need for clinicians to perform rectal exams to identify pelvic floor dysfunction, to validate patients’ pain, and to approach management through a multidisciplinary, empathetic lens.

Data from the ARC-20 trial show promising efficacy and a manageable safety profile for casdatifan monotherapy.

This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.

The addition of radiation after surgery improved clinical outcomes while not increasing severe late toxicity in this setting.

The review summarizes results from the OPTIMA II, ATLAS, and ENVISION trials.

Here’s a look back at notable news between July and September 2025.

Joy Maulik, CRNP, speaks with J. Brandon Arruda, APRN, AGNP-C, CUNP, about the evolving role of advanced practice providers in urology.

Take a look back at the notable regulatory decisions in benign urology between July and September.

The Expert APProach: Conversations in Uro-Oncology, hosted by Joy Maulik, CRNP, is the latest multimedia program from Urology Times.

We recap notable headlines from last month in the urologic oncology space.

We recap notable headlines from last month in the benign urology space.

A recap of the FDA submissions and regulatory decisions in urology from September 2025.

Jason M. Hafron, MD, CMO, reflects on the most impactful recent developments in prostate cancer and offers insight into where the field is headed.

The device features a 12 French working channel, the largest of any flexible single-use cystoscope.

Daniel Spratt, MD, presented data validating the PAM50 gene expression signature as the first predictive biomarker to guide hormone therapy in prostate cancer.

A comprehensive guide to the key regulatory decisions and conferences slated for the last few months of the year.

According to the authors, CAN-2409 may represent the first new treatment option for men with localized prostate cancer in over 2 decades.

The PREDICT-RT trial is evaluating intensified or de-intensified concurrent hormone therapy and radiation regimens in high-risk prostate cancer.